Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.
J Appl Microbiol. 2011 Dec;111(6):1515-23. doi: 10.1111/j.1365-2672.2011.05153.x. Epub 2011 Oct 25.
To evaluate the ability of the broad-spectrum lantibiotic, lacticin 3147, to prevent Streptococcus mutans biofilm formation and disrupt existing biofilms.
Minimum inhibitory concentrations (MIC) and minimum biofilm inhibitory concentrations of purified lacticin 3147 were determined using a microdilution method. Lacticin 3147 effectively inhibited planktonic Strep. mutans, with MIC of 1.9-3.8 μmol l(-1). Time-kill kinetic studies confirmed that lacticin 3147 exhibited bactericidal activity against Strep. mutans at 38 μmol l(-1) (or 10× MIC). The effect of lacticin 3147 on biofilm formation and reduction was also determined. Exposure to 6.3-μmol l(-1) lacticin 3147 (2× MIC) resulted in substantial reductions in Strep. mutans biofilm formation while lacticin 3147 was less effective against 1-day-old biofilms. Culture-based analyses revealed that lacticin 3147 (50 μmol l(-1)) significantly inhibited Streptococcus spp. present in human saliva (P < 0.05) with an approximate 4-log reduction in viability compared with the control.
These results indicate that lacticin 3147 may be an effective therapy against Strep. mutans and was shown to substantially attenuate its ability to form a biofilm.
Lacticin 3147 has the potential to be a useful adjunct to traditional oral therapeutic approaches in addition to its use as a bioactive ingredient for food applications.
评估广谱类细菌素乳链菌肽 3147 抑制变异链球菌生物膜形成和破坏已形成生物膜的能力。
采用微量稀释法测定纯化乳链菌肽 3147 的最小抑菌浓度（MIC）和最小生物膜抑制浓度。乳链菌肽 3147 有效抑制浮游状态的变异链球菌，MIC 为 1.9-3.8 μmol l(-1)。时间杀菌动力学研究证实，乳链菌肽 3147 在 38 μmol l(-1)（或 10×MIC）时对变异链球菌表现出杀菌活性。还确定了乳链菌肽 3147 对生物膜形成和减少的影响。暴露于 6.3-μmol l(-1)乳链菌肽 3147（2×MIC）可显著减少变异链球菌生物膜的形成，而乳链菌肽 3147 对 1 天龄的生物膜效果较差。基于培养的分析表明，乳链菌肽 3147（50 μmol l(-1)）显著抑制了人唾液中的链球菌属（P < 0.05），与对照组相比，其活力约降低了 4 个对数级。
这些结果表明，乳链菌肽 3147 可能是一种有效的治疗变异链球菌的方法，并且可以显著削弱其形成生物膜的能力。
乳链菌肽 3147 除了作为食品应用的生物活性成分外，还有潜力成为传统口腔治疗方法的有用辅助手段。
